SELECT PUBLICATIONS:

The ATAC Trialists’ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 2002;359:2131-9. Abstract

Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 1998;351:1451-67. Abstract

Baum M et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98(9):1802-10. Abstract

Boccardo F et al. Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment. Breast Cancer Res Treat 2003;Abstract 3.

Bundred N, Howell A. Fulvestrant (Faslodex): Current status in the therapy of breast cancer. Expert Rev Anticancer Ther 2002;2(2):151-60. Abstract

Carlson RW. Sequencing of endocrine therapies in breast cancer — integration of recent data. Breast Cancer Res Treat 2002;75(Suppl 1):27-32; discussion 33-5. Abstract

Dow KH. Existing and emerging endocrine therapies for breast cancer. Cancer Nurs 2002;25(Suppl 2):6-11. Abstract

Goss PE et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349(19):1793-802. Abstract

Hancock CM. Fulvestrant antiestrogen for treatment of breast cancer. Clin J Oncol Nurs 2003;7(2):201-2. Abstract

Howell A et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002;20:3396-403. Abstract

Lynn J. The oncology nurse’s role in educating patients on endocrine therapy for metastatic breast cancer — focus on fulvestrant. Cancer Nurs 2002;25(Suppl 2):12-7. Abstract

Lynn J. Estrogen receptor downregulators: New advances in managing advanced breast cancer. Cancer Nurs 2002;25(Suppl 2):2-5; quiz 18-9. Abstract

Osborne CK et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial. J Clin Oncol 2002;20:3386-95. Abstract

Palmieri FM, Perez EA. Recent advances in adjuvant therapy for breast cancer. Semin Oncol Nurs 2003;19(4 Suppl 2):10-6. Abstract

Parker LM. Sequencing of hormonal therapy in postmenopausal women with metastatic breast cancer. Clin Ther 2002;24(Suppl C):43-57. Abstract

Partridge AH et al. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 2003;21(4):602-6. Abstract

Winer EP et al. American Society of Clinical Oncology Technology Assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor positive breast cancer: Status report 2002. J Clin Oncol 2002;20(15):3317-27. Abstract

Winer EP et al. American Society of Clinical Oncology technology assessment working group update: Use of aromatase inhibitors in the adjuvant setting. J Clin Oncol 2003;21(13):2597-9. No abstract available

Home · Search